Truist Securities has reiterated its 'Buy' rating on Axsome Therapeutics and significantly increased its price target from $200 to $285. This analyst upgrade signals increased confidence in the company's future performance and could lead to positive short-term price movement for AXSM.
Truist Securities analyst Srikripa Devarakonda maintained a 'Buy' rating on Axsome Therapeutics and raised the price target from $200 to $285. This substantial increase in the price target, representing a 42.5% jump, indicates a strong bullish outlook from the analyst. For traders, this could signal an immediate positive reaction in AXSM's stock price as the market digests the upgraded valuation. In the short term, this news is likely to generate buying interest, while long-term implications depend on the company's ability to meet or exceed the expectations embedded in this new price target. The key opportunity for traders is to capitalize on potential upward momentum driven by this analyst's increased confidence.